Bentley Systems’ Acceleration Fund Announces the Launch of Virtuosity, a Bentley Company
9.7.2020 16:31:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated, a leading global provider of comprehensive software and digital twins services for advancing the design, construction, and operations of infrastructure, today announced that its Acceleration Fund has invested in launching Virtuosity, a Bentley company. Virtuosity exclusively offers Virtuoso Subscriptions that bundle — with a Bentley infrastructure modeling, simulation, or construction application — the virtually delivered services of Virtuosity’s experts to accelerate and advance the success of an infrastructure practitioner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005552/en/
Allan Murphy, CEO, Virtuosity (Photo: Business Wire)
Virtuoso Subscriptions are now available, at virtuosity.com, for Bentley applications including MicroStation, OpenBridge, OpenBuildings, OpenFlows, OpenRail, OpenRoads, OpenSite, OpenTower, OpenWindPower, AutoPIPE, ContextCapture, LEGION, MOSES, PLAXIS, RAM, SACS, SoilVision, STAAD, and SYNCHRO, and Bentley’s iTwin Design Review cloud service. Virtuosity’s expert services, accessible through Virtuoso Subscription “keys,” include a range of training and one-to-one mentoring activities, and on-demand learning and content, increasingly integrated during actual application usage.
Allan Murphy, Virtuosity CEO, said, “The world’s infrastructure professionals have all gained a new appreciation for what can be achieved through online collaboration. We think this is the perfect time to inaugurate our commercial innovation: a virtuoso subscription that enhances the functionality of a software application through intrinsic assistance from subject matter experts. We’re marshalling and virtualizing our domain expertise to help every infrastructure practitioner perform with the confidence of a virtuoso!”
Werner Felber, Managing Partner, Boley Geotechnick GmbH, Beratende Ingenieure, said, “With Virtuoso Subscriptions, professionals across our international teams can support projects more effectively. Virtuosity’s experts will help keep us current in going digital by constantly leveraging what’s new in Bentley’s applications to ensure our competitiveness in the market and the best results for our customers.”
Image: Virtuosity logo
Image: Allan Murphy headshot
YouTube video: The Value of a Virtuoso Subscription
About Virtuosity, a Bentley Company
Virtuosity is the exclusive global provider of Virtuoso Subscriptions for Bentley Systems’ infrastructure modeling, simulation, and construction applications. Every Virtuoso Subscription—procured through the ecommerce site virtuosity.com—uniquely bundles, with a Bentley software application, virtually delivered services of Virtuosity’s experts to accelerate and advance the success of an infrastructure practitioner.
About Bentley Systems’ Acceleration Fund
Bentley Systems’ Acceleration Fund was founded in 2020 to invest in new and incremental participants in open ecosystems to advance infrastructure digital twins. The Bentley Systems Acceleration Fund is chartered to accelerate the creation and curation of digital twins, and to foster technologies and innovations so enabled, by nurturing new ventures, making minority investments, and acquiring and expanding digital integrators. Investments to date include Digital Water Works, Digital Construction Works, Virtuosity, and The Cohesive Companies. Chief Acceleration Officer Santanu Das welcomes queries from potential ecosystem participants at www.bentleyaccelerationfund.com.
About Bentley Systems
Bentley Systems is a leading global provider of software solutions to engineers, architects, geospatial professionals, constructors, and owner-operators for the design, construction, and operations of infrastructure. Bentley’s MicroStation-based engineering and BIM applications, and its digital twin cloud services, advance the project delivery (ProjectWise) and the asset performance (AssetWise) of transportation and other public works, utilities, industrial and resources plants, and commercial and institutional facilities.
Bentley Systems employs more than 3,500 colleagues and generates annual revenues of more than $700 million in 172 countries. From inception in 1984, the company has remained majority-owned by its five founding Bentley brothers. www.bentley.com
Bentley, the Bentley logo, Bentley Acceleration Fund, AssetWise, AutoPIPE, ContextCapture, iTwin, LEGION, MicroStation, MOSES, OpenBridge, OpenBuildings, OpenFlows, OpenRail, OpenRoads, OpenSite, OpenTower, OpenWindPower, PLAXIS, ProjectWise, RAM, SACS, SoilVision, STAAD, SYNCHRO, Digital Water Works, The Cohesive Companies, Virtuosity, and Virtuoso Subscription are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005552/en/
Contact information
Rachel Rogers
+1 415 827 7347
Rachel.Rogers@bentley.com
Follow us on Twitter:
@BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom